Part 1: Introduction to the main methodological issues in health economic modelling of oncological treatments
Mathematical modelling of oncological treatments is a dynamic field in which methods are constantly adjusted to correspond to the features of novel therapies. The biggest uncertainty in health economic modelling of such cancer therapies originates from survival estimates, typically based on one or a few randomized clinical trials. Methodologically, issues with survival can derive from: cross-over design of a trial, heavy censoring of the patients that results in unreliable predictions beyond time horizon of a trial, lack of head-to-head comparisons of active treatments, plateauing effect on survival of some treatments (e.g. immunotherapies), etc. Within this webinar we will review common challenges in modelling new cancer therapies and discuss different solutions required by the most demanding HTA authorities.
Speaker: Dr Jovan Mihajlović
Jovan Mihajlović is CEO of Mihajlović Health Analytics (MiHA) which he founded in 2013 as a spin-off company to the University of Groningen. Jovan obtained the Master’s degree in pharmacy in 2006, and defended his PhD thesis “Health Economics of Targeted Cancer Therapies“ at the University of Groningen, the Netherlands, in 2016. He focussed his research on methodological aspect of modelling targeted cancer therapies, in particular on survival analysis and simultaneous comparisons through network meta-analysis. Subsequently, he published several studies in renowned journals, was speaker at numerous health economic and oncological professionals’ meetings, regularly exhibited his work at the biggest pharmacoeconomic conferences and was appointed reviewer of several scientific journals. Parallel to his scientific research, through MiHA Jovan was developing health economics consultancy services to the industry and academia. He designed and adjusted cost-effectiveness and budget impact models, conducted epidemiological studies, systematic reviews, network meta-analyses and completed pharmacoeconomic dossiers for more than 70 medicines and medical devices for the industry, academia and other consultancies in the Netherlands, Belgium, the United Kingdom, Slovenia and Serbia.
Register for the follow-up webinar scheduled on 23 Oct 2019